Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Secondary Lymphoid Organs

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

Lymphoid Cells and Tissues

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

Treatment Resistent Cancers

Treatment Resistent Cancers

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026

Same author

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Blood advances·2026

Same author

A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.

American journal of hematology·2025

Same author

Primum succurrere; first hasten to help.

The oncologist·2025

Same author

Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.

Leukemia & lymphoma·2025

Same author

Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma: A Narrative Review.

JAMA oncology·2025

Same journal

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026

Same journal

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

American journal of hematology·2026

Same journal

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

American journal of hematology·2026

Same journal

Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL.

American journal of hematology·2026

Same journal

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

American journal of hematology·2026

Same journal

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

American journal of hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

The aggressive peripheral T-cell lymphomas: 2015.

James O Armitage¹

¹University of Nebraska Medical Center, Omaha, Nebraska.

American Journal of Hematology

|June 3, 2015

Summary

This summary is machine-generated.

Peripheral T-cell lymphomas (PTCL) are aggressive lymphoid malignancies with variable incidence. Diagnosis and risk stratification are challenging, necessitating tailored therapies for subtypes like anaplastic large-cell lymphoma.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Apr 11, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

Hematology
Oncology
Pathology

Background:

Peripheral T-cell lymphomas (PTCL) constitute 10%-15% of lymphoid malignancies.
PTCL incidence shows geographic variation, being highest in parts of Asia.

Purpose of the Study:

To review the diagnostic, risk stratification, and therapeutic approaches for aggressive PTCL.
To highlight challenges in PTCL diagnosis and the need for subtype-specific treatments.

Main Methods:

Diagnosis relies on the World Health Organization classification, with variable inter-observer reproducibility.
Staging employs the Ann Arbor Classification and positron emission tomography scans.
Risk stratification uses the International Prognostic Index and considers specific PTCL subtypes.

Main Results:

Anaplastic large-cell lymphoma (ALCL) shows good response to CHOP-like regimens, especially in young, ALK-positive patients.
Angioimmunoblastic T-cell lymphoma (AITL) has poor prognosis, though autotransplantation may benefit younger patients.
Other subtypes like PTCL-not otherwise specified (NOS), natural killer/T-cell lymphoma (NKTCL), enteropathy-associated T-cell lymphoma (EATL), and hepatosplenic T-cell lymphoma (HSTCL) have varied responses to therapy.

Conclusions:

Aggressive PTCL diagnosis and prognostication require careful consideration of subtype.
Risk-adapted therapy is crucial, with distinct strategies for ALCL, AITL, NKTCL, EATL, and HSTCL.
New therapeutic approaches are needed for PTCL subtypes with poor responses to current regimens.